Get startedLog in
    Picture of AstraZeneca logo

    AZN — AstraZeneca Cashflow Statement

    0.000.00%
    gb flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for AstraZeneca, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSPRESS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS    		—
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-2652,5016,8998,69112,402
    Depreciation
    Non-Cash Items1415421,2061,4381,738
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital-4431,285-3,147-4,956-5,298
    Change in Accounts Receivable
    Change in Inventories
    Change in Payable / Accrued Expenses
    Net Change in Other Assets & Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities5,9639,80810,34511,86114,575
    Capital Expenditures-2,200-2,571-3,778-4,586-5,905
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-8,858-389-286-3,394-903
    Acquisition of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Sale of Intangible Assets
    Other Investing Cash Flow
    Cash from Investing Activities-11,058-2,960-4,064-7,980-6,808
    Financing Cash Flow Items-178-1,047-886-817-70
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities3,649-6,823-6,567-3,996-7,544
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-1,508-55-346-208269